Merck to Acquire CN201, Expanding B-cell Disease Treatment Pipeline
Key Highlights Merck to acquire CN201, a clinical-stage bispecific antibody targeting B-cell diseases. Transaction valued at $700M upfront,…
Browsing Tag
Dr. Dean Y. Li
2 posts
Merck to Acquire Eyebiotech Limited for $3 Billion
Key Highlights Merck acquires Eyebiotech for up to $3 billion Eyebiotech’s Restoret™ to advance into pivotal trials in…